Controlled clinical comparison of paroxitine and fluvoxamine considering the serotonin transporter promoter polymorphism

International Clinical Psychopharmacology

Volumn 20, Issue 3, 2005, Pages 151-156

  Kato, Masaki ^a   Ikenaga, Yuka ^b   Wakeno, Masataka ^a   Okugawa, Gaku ^a   Nobuhara, Kenji ^a   Fukuda, Tsuyoshi ^b   Fukuda, Kazuhiro ^b   Azuma, Junichi ^b   Kinoshita, Toshihiko ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Depression; Fluvoxamine; Paroxetine; Serotonin transporter; SSRIs; Treatment response

Indexed keywords

FLUVOXAMINE; PAROXETINE; SEROTONIN TRANSPORTER;

ADULT; AGED; AMNESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEROTONIN RELEASE; SEXUAL DYSFUNCTION; SIDE EFFECT; VERTIGO;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSIVE DISORDER; FEMALE; FLUVOXAMINE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PAROXETINE; PATIENT DROPOUTS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PSYCHIATRIC STATUS RATING SCALES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 17644379922     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200505000-00005     Document Type: Article

References (24)

1. Ali IM (1998). Long-term treatment with antidepressants in primary care. Psychiatr Bull 22:15-19.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
3. Ansseau M, Gabriels A, Loyens J, Bartholome F, Evrard JL, De Nayer A, et al. (1994). Controlled comparison of paroxetine and fluvoxamine in major depression. Hum Psychopharmacol 9:329-336.
4. Deckert J, Catalano M, Helis A, Di Bella D, Friess F, Politi E, et al. (1997). Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder. Psychiatr Genet 7:45-47.
5. Fava M (2000). Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 61 (suppl 2):10-12.
6. Fava M, Davidson KG (1996). Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179-200.
7. Goldstein BJ, Goodnick PJ (1998). Selective serotonin reuptake inhibitors in the treatment of affective disorders - olerability, safety and pharmacoeconomics. J Psychopharmacol 12 (suppl B):S55-S87.
8. Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Pshchol 6:278-296.
9. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, et al. (1996). Allelic variation of human serotonin transporter gene expression. J Neurochem 66:2621-2624.
10. Hiemke C, Hartter S (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85:11-28.
11. Horton RW, De Paermentier F, Lowther S, Lawrence KM, Compton MR, Tulloch IF (1993). The interaction of antidepressant drugs with neurotransmitter receptor binding sites and 5-HT uptake sites in human brain in vitro. Eur Neuropsychopharmacol 3:344-345.
12. Jonson AM (1991). The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In: Feigner JP, Boyer WF (editors): Perspectives in Psychiatry: Selective Serotonin Re-uptake Inhibitors, vol. 1. Chichester: John Wiley; pp. 37-70.
13. Kevin A, Feiger A (1997). A double-blind comparison of fluvaoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 58:146-152.
14. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. (2001). CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104:173-192.
15. Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T, et al. (1997). Serotonin transporter polymorphism: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 2:457-462.
16. Lesch KP, Bengel D, Helis A, Sabol S, Grrenberg BD, Petri S, et al. (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
17. Lucca A, Lucini V, Catalano M, Alfano M, Smeraldi E (1994). Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonine uptake inhibitor. Neuropsychobiology 29: 108-111.
18. Pollock BG, Ferrell RE, Mulsant BH, Mazumbar S, Miller M, Sweet RA, et al. (2000). Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587-590.
19. Serretti A, Cusin C, Lattuada E, Di Bella D, Catalano M, Smeraldi E (1999). Serotonin transporter gene (5HTTLPR) is not associated with depressive symptomatology in mood disorder. Mol Psychiatry 4:280-283.
20. Serretti A, Artioli P (2004). The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics 4:233-244.
21. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998). Polymorphism within the promoter of serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508-511.
22. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, et al. (2002). Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 26:383-386.
23. Yu YW-Y, Tsai S-J, Chen T-J, Lin C-H, Hong C-J (2002). Association study of the serotonin transporter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7:1115-1119.
24. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000). Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20:105-107.